Skip to content
Home/Companies/Healthcare/Ten63 Therapeutics
Ten63 Therapeutics

Ten63 Therapeutics

Healthcare·United States·Active·New
Entry
2026
Hold
New
Status
Active

Who owns Ten63 Therapeutics?

Ten63 Therapeutics is currently owned by Ryse Asset Management through RYSE Special Opportunities Fund (2024 vintage), since 2026.

Hand-verified · updated 2026-04-21

Ryse Asset Management
Investor
Ryse Asset Management
RYSE Special Opportunities Fund · 2024 · VC

Key facts

HQUK
SectorHealthcare
Websitewww.ten63tx.com

More from RYSE Special Opportunities Fund

Other portfolio companies in the same fund.

Braingaze
Braingaze
Active
HealthTechSpain· 2024
Curio Digital Therapeutics
Curio Digital Therapeutics
Active
HealthTechUnited States· 2024
Oto
Oto
Active
HealthTechUnited Kingdom· 2022
Knok
Knok
Active
HealthTechPortugal· 2020
Log My Care
Log My Care
Active
HealthTechUnited Kingdom· 2020

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Ten63 Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Ten63 Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue